Author

Julie Radermecker

Lyon 1 Université

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Angéline Gaucherot· 1 shared Camille Jouines· 1 shared Carine FromentiD· 1 shared Caroline IsaaciD· 1 shared Christophe VanbelleiD· 1 shared Fleur BourdelaisiD· 1 shared Flora Nguyen Van LongiD· 1 shared Frédéric CateziD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Angéline Gaucherot

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Fibrillarin-mediated ribosomal RNA maturation is a novel therapeutic vulnerability in triple-negative breast cancer

Camille Jouines, Piero Lo Monaco, Angéline Gaucherot, Julie Radermecker, Caroline Isaac, Fleur Bourdelais, Marie‐Ambre Monet, Marion Meyer, Mounira Chalabi‐Dchar, Flora Nguyen Van Long, Laury Baillon, Carine Froment, Julien Marcoux, Christophe Vanbelle, Tanguy Fenouil, , Frédéric Catez

This study identifies ribosome biogenesis as a therapeutic vulnerability in TNBC, showing that inhibiting rRNA maturation via Fibrillarin or RNA Pol I reduces tumor growth without significant cell death.

Breast Cancer Research · Nov 13, 2025Peer-reviewedCancer Biology